Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 6/20 | 0.42 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 3/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21270200 | 1.00 | BDKRB1 (0.42) | BDKRB1GPER1LMNAHPGDDGAT1 | |
| SCHEMBL21270929 | 0.90 | SMPD1 (0.36) | BDKRB1LMNASMPD1HDAC4HDAC6 | |
| SCHEMBL21178348 | 0.90 | SMPD1 (0.36) | BDKRB1LMNASMPD1HDAC4HDAC6 | |
| SCHEMBL21270987 | 0.90 | DGAT1 (0.37) | BDKRB1DGAT1SMPD1WDR5 | |
| SCHEMBL21270982 | 0.90 | DGAT1 (0.37) | BDKRB1DGAT1SMPD1WDR5 | |
| Aficamten SCHEMBL21179172 | 0.85 | BTK (0.44) | BDKRB1SMPD1WDR5 | |
| Aficamten SCHEMBL21179170 | 0.85 | BTK (0.44) | BDKRB1SMPD1WDR5 | |
| Aficamten SCHEMBL30167980 | 0.85 | BTK (0.44) | BDKRB1SMPD1WDR5 | |
| SCHEMBL21270163 | 0.83 | WDR5 (0.38) | BDKRB1LMNAHPGDWDR5 | |
| SCHEMBL21270159 | 0.83 | WDR5 (0.38) | BDKRB1LMNAHPGDWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | claimed |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12065436-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11472796-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885GPER1 3806/4885LMNA 62/4885 |
| US-10836755-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885GPER1 3806/4885LMNA 62/4885 |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885GPER1 3806/4885LMNA 62/4885 |
| US-12065436-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885GPER1 3806/4885LMNA 62/4885 |
| US-11472796-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885GPER1 3806/4885LMNA 62/4885 |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885GPER1 3806/4885LMNA 62/4885 |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | BDKRB1 1489/4885GPER1 3806/4885LMNA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.